Sermorelin
Also Known As: GRF 1-29, Sermorelin Acetate, Geref, Gerel, GRF(1-29)-NH2, Growth hormone releasing factor 1-29, GHRH 1-29, Natural GHRH analog, Sermorelin diagnostic, Sermorelin anti-aging, Sermorelin GHRH peptide, Growth releasing factor, GH stimulation peptide, GHRH 1-29 amide, GHRH, geref
Sermorelin is a research-grade Synthetic 29-amino acid fragment of endogenous GHRH targeting GHRH receptor studied in Muscle Growth & Performance research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Approved Drug - FDA and/or EMA approved with robust human trial data.
A growth-hormone-releasing hormone analog formerly approved for childhood GH deficiency; banned in sport.
At A Glance
| Category | Muscle Growth & Performance |
|---|---|
| Compound Class | Synthetic 29-amino acid fragment of endogenous GHRH (GHRH 1-29-NH2) |
| Molecular Target | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release |
| Molecular Weight | 3357.93 Da |
| Amino Acid Sequence | GHRH(1-29) amide |
| CAS Number | 86168-78-7 |
| Half-Life | ~10-20 min |
| WADA Status | prohibited |
| Evidence Tier | Approved Drug |
Mechanism Of Action
It provides the shortest active sequence of Growth Hormone-Releasing Hormone (GHRH), binding to the pituitary to trigger a completely natural, mild pulse of growth hormone during sleep.
Studied For
- Pituitary GH-reserve diagnostic
- Pediatric GH deficiency (historical)
- Adult GH-axis / anti-aging research
- GH secretagogue research
- IGF-1 elevation
- Body composition / lean mass
- Fat loss via GH axis
- Bone density support
- Sleep quality via GH
- Recovery and repair
- GH deficiency models
- Metabolic rate improvement
- Collagen synthesis via GH
- Anti-aging longevity research
- GH replacement alternative
- anti-aging
- growth hormone secretagogue
- sleep improvement
- vitality
- body composition
- pituitary health
Reported Research Findings
As the former drug Geref it increased growth velocity in deficient children and produced a reliable growth-hormone rise in stimulation testing. The branded product was withdrawn for commercial reasons, not safety.
Safety And Handling Notes
Injection-site reactions, flushing, headache, dizziness, nausea; rare hypersensitivity; antibody formation with chronic pediatric use.
Requires a functional pituitary; response is blunted by obesity and high blood sugar. WADA-prohibited. Now dispensed as a compounded prescription in the US.
Regulatory Status
Was FDA-approved (withdrawn for commercial reasons); now compounded Rx; WADA S2.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.